MYC gene amplification or deregulation is estimated in up to 70% of human cancers and has been linked to the tumorigenicity of many cancers.31 The emerging role of BET proteins as the inhibitors of MYC suggests that the BET protein BETi may become a therapeutic option for these cancers. The gene discussed is MYC; the disease is cancer.